Jamie Dimon Is Now a Billionaire
The vast majority of the billionaires in the U.S. made their money in one of two ways—they started a company, or they inherited their fortune or business.
But Jamie Dimon, chairman and CEO of JPMorgan Chase, has shown another path to riches. As a corporate manager, he may have amassed enough stock and boosted the share price enough to join the 10-figure club.
According to Bloomberg, Dimon is now worth $1.1 billion. His stake in JPMorgan through shares and options is worth $485 million and he also has real estate valued at $32 million. In addition, he has wealth from "an investment portfolio seeded by proceeds" from his previous stint at Citigroup.
Related: America’s Highest Paid CEO: It’s Not Who You Think
While highly unusual, Dimon isn't the first billionaire professional manager or executive who gained his wealth from stock in a company he didn't found or take public. The first manager-billionaire in the U.S. was believed to be Roberto Goizueta, CEO of Coca-Cola during the 1980s and 1990s. During his tenure, Coca-Cola's stock jumped more than 70-fold and Goizueta had stock and options totaling more than $1 billion.
More recently, the billionaire managers have been from finance. James Cayne, the colorful CEO and chairman of Bear Stearns became a billionaire on paper—before Bear Stearns collapsed during the financial crisis.
Richard Fuld, CEO of Lehman Brothers, also became a paper billionaire in 2007—before the investment bank became the largest bankruptcy in U.S. history in 2008.
Plenty of other finance chiefs have become billionaires—from hedge-funders to private-equity kings Steve Schwarzman and David Rubenstein. Citi founder Sandy Weill was a billionaire, but he created the company.
So while he may not be the first, Dimon may make history another way—by becoming the first manager-billionaire in finance to run a bank that thrives for decades after his leadership.
This article originally appeared on CNBC.
Read more from CNBc.
CNBC Charts the top 100 firms
Shift from slaes to planning fuels fee-only business
Harvard Receives Laegest Ever Gift
Tax Refunds Rebound
Smaller refunds in the first few weeks of the current tax season were shaping up to be a political problem for Republicans, but new data from the IRS shows that the value of refund checks has snapped back and is now running 1.3 percent higher than last year. The average refund through February 23 last year was $3,103, while the average refund through February 22 of 2019 was $3,143 – a difference of $40. The chart below from J.P. Morgan shows how refunds performed over the last 3 years.
Number of the Day: $22 Trillion
The total national debt surpassed $22 trillion on Monday. Total public debt outstanding reached $22,012,840,891,685.32, to be exact. That figure is up by more than $1.3 trillion over the past 12 months and by more than $2 trillion since President Trump took office.
Chart of the Week: The Soaring Cost of Insulin
The cost of insulin used to treat Type 1 diabetes nearly doubled between 2012 and 2016, according to an analysis released this week by the Health Care Cost Institute. Researchers found that the average point-of-sale price increased “from $7.80 a day in 2012 to $15 a day in 2016 for someone using an average amount of insulin (60 units per day).” Annual spending per person on insulin rose from $2,864 to $5,705 over the five-year period. And by 2016, insulin costs accounted for nearly a third of all heath care spending for those with Type 1 diabetes (see the chart below), which rose from $12,467 in 2012 to $18,494.
Chart of the Day: Shutdown Hits Like a Hurricane
The partial government shutdown has hit the economy like a hurricane – and not just metaphorically. Analysts at the Committee for a Responsible Federal Budget said Tuesday that the shutdown has now cost the economy about $26 billion, close to the average cost of $27 billion per hurricane calculated by the Congressional Budget Office for storms striking the U.S. between 2000 and 2015. From an economic point of view, it’s basically “a self-imposed natural disaster,” CRFB said.
Chart of the Week: Lowering Medicare Drug Prices
The U.S. could save billions of dollars a year if Medicare were empowered to negotiate drug prices directly with pharmaceutical companies, according to a paper published by JAMA Internal Medicine earlier this week. Researchers compared the prices of the top 50 oral drugs in Medicare Part D to the prices for the same drugs at the Department of Veterans Affairs, which negotiates its own prices and uses a national formulary. They found that Medicare’s total spending was much higher than it would have been with VA pricing.
In 2016, for example, Medicare Part D spent $32.5 billion on the top 50 drugs but would have spent $18 billion if VA prices were in effect – or roughly 45 percent less. And the savings would likely be larger still, Axios’s Bob Herman said, since the study did not consider high-cost injectable drugs such as insulin.
